San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, RayzeBio is raising $105,000,012.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ken Song played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RayzeBio

Despite therapeutic advances made in the last decade, there remains a high unmet need for new cancer treatments. Radiation therapy is a proven approach to treating many cancers and is typically administered by an external beam of high energy rays. In contrast, radiopharmaceuticals deliver radioisotopes to tumors via the bloodstream. Radiopharmaceuticals have the unique advantage of being both diagnostic and therapeutic. The same drug conjugate could be used for both diagnostic imaging and therapeutic use by switching out the radioisotope. Direct visualization of drug conjugate uptake by tumors with imaging allows for proper patient selection to receive the therapeutic radioisotope (e.g. Actinium-225).

To learn more about RayzeBio, visit http://rayzebio.com/

Contact:
Ken Song, Chief Executive Officer
415-412-5509
https://www.linkedin.com/in/kssong/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved